ARWR (Arrowhead Pharmaceuticals) Cyclically Adjusted PB Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ARWR Arrowhead Pharmaceuticals Inc ARWR
49 GF Score
Price $69.28
GF Value $48.86
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Arrowhead Pharmaceuticals Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Arrowhead Pharmaceuticals  (NAS:ARWR) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Arrowhead Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms


Arrowhead Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Arrowhead Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arrowhead Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Arrowhead Pharmaceuticals Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.47 11.97 8.88 6.79 11.28

Arrowhead Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.87 10.46 19.89 18.10 22.94

ARWR vs HALO, CORT, MDGL: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Arrowhead Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arrowhead Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arrowhead Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Arrowhead Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


ARWR
49GF Score
Arrowhead Pharmaceuticals Inc ARWR
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arrowhead Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Arrowhead Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Arrowhead Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=3.302/333.9520*333.9520
=3.302

Current CPI (Jun. 2026) = 333.9520.

Arrowhead Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201609 1.362 241.428 1.884
201612 1.306 241.432 1.806
201703 1.248 243.801 1.709
201706 1.198 244.955 1.633
201709 1.081 246.819 1.463
201712 0.937 246.524 1.269
201803 1.299 249.554 1.738
201806 1.158 251.989 1.535
201809 1.076 252.439 1.423
201812 1.852 251.233 2.462
201903 2.119 254.202 2.784
201906 2.370 256.143 3.090
201909 2.555 256.759 3.323
201912 4.940 256.974 6.420
202003 4.851 258.115 6.276
202006 4.817 257.797 6.240
202009 4.511 260.280 5.788
202012 4.404 260.474 5.646
202103 4.283 264.877 5.400
202106 4.192 271.696 5.153
202109 3.919 274.310 4.771
202112 3.555 278.802 4.258
202203 4.279 287.504 4.970
202206 4.482 296.311 5.051
202209 3.948 296.808 4.442
202212 3.734 296.797 4.201
202303 4.352 301.836 4.815
202306 3.567 305.109 3.904
202309 2.676 307.789 2.903
202312 1.616 306.746 1.759
202403 3.991 312.332 4.267
202406 2.729 314.175 2.901
202409 1.536 315.301 1.627
202412 0.447 315.605 0.473
202503 4.956 319.799 5.175
202506 3.763 322.561 3.896
202509 3.710 324.800 3.815
202512 4.096 324.054 4.221
202603 4.261 330.213 4.309
202606 3.302 333.952 3.302

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Arrowhead Pharmaceuticals (ARWR) Overvalued in 2026?

Based on GuruFocus' analysis, Arrowhead Pharmaceuticals stock appears to be overvalued. The current stock price of $69.28 is trading 41.8% above its estimated GF Value™ of $48.86. GuruFocus considers Arrowhead Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for ARWR:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: $48.86 vs. price of $69.28 (41.8% above fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the ARWR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Arrowhead Pharmaceuticals Business Description

Address 177 E Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
49GF Score

Get the complete analysis for ARWR

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$69.28
Price
$48.86
GF Value